search
Back to results

Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence

Primary Purpose

Alcohol Dependence

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Psilocybin
Sponsored by
University of New Mexico
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alcohol Dependence focused on measuring alcohol dependence, psilocybin, clinical trial, motivational enhancement therapy

Eligibility Criteria

25 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Males and females age 25-65 with SCID diagnosis of alcohol dependence;
  2. Concerned about their drinking, but not planning to pursue any other form of treatment at present (12-step meetings are not considered treatment);
  3. Able to provide voluntary informed consent;
  4. Having at least 2 heavy drinking days in the past 30 days;
  5. Willing to commit to the goal of abstinence at least from the time of the first psilocybin administration session until the end of treatment.
  6. At least 24 hours abstinence from alcohol at the time of the psilocybin administration sessions;
  7. If female of childbearing potential, willing to use approved form of contraception from screening until after the psilocybin administration sessions;
  8. Having a family member or friend who can pick them up and stay with them overnight after the psilocybin administration sessions; and
  9. Able to provide adequate locator information.

Exclusion Criteria:

  1. Exclusionary medical conditions (e.g., seizure disorder, significantly impaired liver function, coronary artery disease, uncontrolled hypertension, history of cerebrovascular accident, severe obesity (BMI greater than or equal to 35);
  2. Exclusionary psychiatric conditions (schizophrenia, schizoaffective disorder, bipolar disorder, current major depression, current post-traumatic stress disorder, current suicidality);
  3. A family history of schizophrenia, schizoaffective disorder, bipolar disorder, or suicide (first or second degree relatives);
  4. Lifetime history of hallucinogen use on more than 10 occasions, or any use in the past 30 days;
  5. Cocaine, psychostimulant, or opioid dependence (past 12 months) or current (past 30 days) use;
  6. A history of medically significant suicide attempt or violent crime;
  7. Significant alcohol withdrawal (CIWA-Ar score greater than 7);
  8. Exclusionary laboratory abnormalities (any liver function test (LFT) greater than 5 times normal, ECG evidence of ischemia, serious abnormalities of complete blood count or chemistries);
  9. Active legal problems with the potential to result in incarceration;
  10. Pregnancy or lactation;
  11. The need to take excluded medication (e.g., antidepressants, antipsychotics, psychostimulants, pharmacologic treatments for addictions).
  12. High risk of adverse emotional reaction based on investigator's clinical evaluation (e.g., evidence of serious personality disorder, serious current stressors, lack of meaningful social support).

Sites / Locations

  • University of New Mexico Health Sciences Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

psilocybin

Arm Description

Outcomes

Primary Outcome Measures

Change in Percent Heavy Drinking Days

Secondary Outcome Measures

Full Information

First Posted
February 13, 2012
Last Updated
September 6, 2023
Sponsor
University of New Mexico
Collaborators
Heffter Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT01534494
Brief Title
Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence
Official Title
Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
January 2012 (undefined)
Primary Completion Date
September 2013 (Actual)
Study Completion Date
March 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of New Mexico
Collaborators
Heffter Research Institute

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This trial is an open-label pilot study (N = 10) designed to assess the effects of psilocybin in alcohol dependent participants, demonstrate the feasibility of the integrated behavioral/pharmacologic intervention, and provide preliminary outcome and safety data. Participants will receive psilocybin orally in two all-day administration sessions, conducted in a secure outpatient psychiatric setting, in a dose range that has been well-tolerated in recent studies. Psilocybin administration will occur in the context of a behavioral intervention including a total of 12 sessions over 12 weeks, incorporating Motivational Enhancement Therapy (MET (Miller, Zweben et al. 1992; Miller 1995), based on Motivational Interviewing (Miller and Rollnick 2002)) with booster sessions, as well as preparation before and debriefing after the psilocybin administration sessions. The MET will incorporate attention to spirituality as well as drinking behavior as a primary subject of change. Drinking outcomes and changes in several potential mediators of treatment effect, including motivation, self-efficacy, craving, depression, anxiety, and spiritual dimensions of the experience, will be measured during treatment and for 24 weeks after the end of treatment. The investigators hypothesize that drinking will decrease following the psilocybin sessions, and that increases in motivation, self-efficacy, and spirituality (primary contrast 12 weeks vs. baseline) will be observed among study participants.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alcohol Dependence
Keywords
alcohol dependence, psilocybin, clinical trial, motivational enhancement therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
psilocybin
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Psilocybin
Intervention Description
two doses of 0.3 mg/kg PO and 0.4 mg/kg PO, separated by 4 weeks in combination with 12 weeks of manualized outpatient psychosocial treatment including preparation, debriefing, and motivational enhancement therapy.
Primary Outcome Measure Information:
Title
Change in Percent Heavy Drinking Days
Time Frame
weeks 5-12 post initiation of treatment vs. 12 weeks prior to treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males and females age 25-65 with diagnosis of alcohol dependence, as ascertained using the Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders (DSM-IV version); Concerned about their drinking, but not planning to pursue any other form of treatment at present (12-step meetings are not considered treatment); Able to provide voluntary informed consent; Having at least 2 heavy drinking days in the past 30 days; Willing to commit to the goal of abstinence at least from the time of the first psilocybin administration session until the end of treatment. At least 24 hours abstinence from alcohol at the time of the psilocybin administration sessions; If female of childbearing potential, willing to use approved form of contraception from screening until after the psilocybin administration sessions; Having a family member or friend who can pick them up and stay with them overnight after the psilocybin administration sessions; and Able to provide adequate locator information. Exclusion Criteria: Exclusionary medical conditions (e.g., seizure disorder, significantly impaired liver function, coronary artery disease, uncontrolled hypertension, history of cerebrovascular accident, severe obesity (BMI greater than or equal to 35); Exclusionary psychiatric conditions (schizophrenia, schizoaffective disorder, bipolar disorder, current major depression, current post-traumatic stress disorder, current suicidality); A family history of schizophrenia, schizoaffective disorder, bipolar disorder, or suicide (first or second degree relatives); Lifetime history of hallucinogen use on more than 10 occasions, or any use in the past 30 days; Cocaine, psychostimulant, or opioid dependence (past 12 months) or current (past 30 days) use; A history of medically significant suicide attempt or violent crime; Significant alcohol withdrawal (CIWA-Ar score greater than 7); Exclusionary laboratory abnormalities (any liver function test (LFT) greater than 5 times normal, ECG evidence of ischemia, serious abnormalities of complete blood count or chemistries); Active legal problems with the potential to result in incarceration; Pregnancy or lactation; The need to take excluded medication (e.g., antidepressants, antipsychotics, psychostimulants, pharmacologic treatments for addictions). High risk of adverse emotional reaction based on investigator's clinical evaluation (e.g., evidence of serious personality disorder, serious current stressors, lack of meaningful social support).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael P Bogenschutz, M.D.
Organizational Affiliation
University of New Mexico
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of New Mexico Health Sciences Center
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87131
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence

We'll reach out to this number within 24 hrs